Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC

NCT05846646 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

6

Enrollment

INDUSTRY

Sponsor class

Stopped Change in ImmuneSensor corporate strategy.

Conditions

Oligometastatic Disease

Interventions

DRUG: IMSA101
DRUG: Immune checkpoint inhibitor
RADIATION: PULSAR

Sponsor

ImmuneSensor Therapeutics Inc.